Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia

Journal of Critical Care

Volumn 25, Issue 1, 2010, Pages 69-77

  Nicasio, Anthony M ^a   Eagye, Kathryn J ^a   Nicolau, David P ^a   Shore, Eric ^a,b   Palter, Marc ^a   Pepe, Judith ^a,b   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; ICU; Mortality; Pharmacodynamics; Resistance; Ventilator associated pneumonia

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NEUROTOXICITY; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT DISEASE; SEIZURE; SIDE EFFECT; SUPERINFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CRITICAL PATHWAYS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; OBSERVATION; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS; TOBRAMYCIN; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 77049103406     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2009.02.014     Document Type: Article

References (25)

1. Safdar N., Dezfulian C., Collard H.R., et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 33 (2005) 2184-2193
2. American Thoracic Society and the Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
3. Iregui M., Ward S., Sherman G., et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122 (2002) 262-268
4. Luna C.M., Aruj P., Niederman M.S., et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 27 (2006) 158-164
5. Kuti E.L., Patel A.A., and Coleman C.I. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infections: a meta-analysis. J Crit Care 23 (2008) 91-100
6. Trouillet J.L., Chastre J., Vuagnat A., et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157 (1998) 531-539
7. Beardsley J.R., Williamson J.C., Johnson J.W., et al. Using local microbiological data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 130 (2006) 787-793
8. Ibrahim E.H., Ward S., Sherman G., et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 29 (2001) 1109-1115
9. Soo Hoo G.W., Wen Y.E., Nguyen T.V., et al. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 128 (2005) 2778-2787
10. Gillespie E.L., Kuti J.L., and Nicolau D.P. When "S" doesn't mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infections. Conn Med 69 (2005) 203-210
11. Drusano G.L. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 36 (2003) S42-S50
12. Kashuba A.D., Nafziger A.N., Drusano G.L., et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 43 (1999) 623-629
13. Lorente L., Lorenzo L., Martin M.M., et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 40 (2006) 219-223
14. Lodise Jr. T.P., Lomaestro B.M., and Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44 (2007) 357-363
15. Lorente L., Jimenez A., Palmero S., et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 29 (2007) 2433-2439
16. Chastre J., Wunderink R., Prokocimer P., et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 36 (2008) 1089-1096
17. Deryke C.A., Kuti J.L., and Nicolau D.P. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 27 (2007) 333-342
18. Nicolau D.P., Freeman C.D., Belliveau P.P., et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 39 (1995) 650-655
19. Lancaster J.W., Lawrence K.R., Fong J.J., et al. Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomes. Pharmacotherapy 28 (2008) 852-862
20. Kuti J.L., Moss K.M., Nicolau D.P., et al. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 24 (2004) 1641-1645
21. Kuti J.L., Dandekar P.K., Nightingale C.H., et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharm 43 (2003) 1116-1123
22. Tam V.H., Louie A., Lomaestro B.M., et al. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiological surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 23 (2003) 291-295
23. Mohr J.F., Wanger A., and Rex J.H. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 48 (2004) 125-130
24. Garnacho-Montero J., Sa-Borges M., Sole-Violan J., et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 35 (2007) 1888-1895
25. Bassetti M., Righi E., and Viscoli C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy. Curr Med Chem 15 (2008) 517-522